News Release - February 15, 2018

TEL AVIV, Israel, Feb. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Perflow Medical, an Israeli-based medical device company that develops innovative tools for neurovascular interventions, today announced that the company has closed $12 million in financing. The syndicate included existing investors, two new international investors, and an unnamed strategic investor. Following a recent launch in Europe, Perflow stated that over 50 mechanical thrombectomy procedures for the treatment of acute ischemic stroke have been successful completed with the Stream™ Dynamic Neuro-Thrombectomy Net.

The new investment will support the commercialization of their first product, the Stream Net device, in Europe and select other countries and submission of the U.S. FDA 510(k) dossier. It will also support product development of two new products based on their patent-protected CEREBRAL NET™ Technology platform for aneurysm neck bridging and flow diversion procedures.

Interventional Neurologist Marc Ribó, MD, PhD, at Hospital Vall d'Hebron in Barcelona, Spain and Interventional Neuroradiologist Anastasios Mpotsaris, MD, PhD, at Uniklinikum Aachen, Germany were the first physicians to use the novel device. "The Stream Net offers a new level of control that expands a physician's options to respond in real-time. My early experience with the system has been positive and I see it as a valuable addition to the market," commented Dr. Ribó. Sharing his experience Prof. Dr. med. Mpotsaris added, "The Stream's unique braided net design and device control help with clot retention during revascularization."

A next-generation thrombectomy device, the Stream Net is designed to address unmet clinical needs in the treatment of acute ischemic stroke, a leading cause of long-term disability that accounts for 5.5 million deaths annually worldwide. It offers the physician full device control of the braided net diameter, length, and radial force to create dynamic wall apposition and better clot retention during revascularization in tortious anatomy.

"This financing is a significant step and reflects the strong commitment our investors have to Perflow and the value of our proprietary CEREBRAL NET technology to empower physicians to improve outcomes," stated Danny Farin, CEO of Perflow Medical. "The clinical experience of the Stream Net device in Europe has been very encouraging and these funds will accelerate our ability to bring this life-saving technology to the market and continue to iterate novel neurovascular solutions using CEREBRAL NET technology."